ConductScience.org, home

Paper39091016

Gilteritinib Reduces FLT3 Expression in Acute Myeloid Leukemia Cells.

Thái TL and 1 other. Biomol Ther (Seoul), 2024. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Gilteritinib Reduces FLT3 Expression in Acute Myeloid Leukemia Cells. Papers, record 39091016. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39091016

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Gilteritinib Reduces FLT3 Expression in Acute Myeloid Leukemia Cells.
PubMed
Journal
Biomol Ther (Seoul)
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.19, provisional
iCite
Revised in PubMed
2024-09-15
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Thái TLThị Lam
2Han SYSun-Young

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131528345Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.Biomark Res2019https://conductscience.org/library/papers/31528345PubMed
231309543Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.Br J Haematol2019https://conductscience.org/library/papers/31309543PubMed
331493406Hematological malignancies and molecular targeting therapy.Eur J Pharmacol2019https://conductscience.org/library/papers/31493406PubMed
437433680Evaluation of hypereosinophilia in a case of FLT3-mutant acute myeloid leukemia treated with gilteritinib.Cold Spring Harb Mol Case Stud2023https://conductscience.org/library/papers/37433680PubMed
536518702Development of Gilteritinib-Based Chimeric Small Molecules that Potently Induce Degradation of FLT3-ITD Protein.ACS Med Chem Lett2022https://conductscience.org/library/papers/36518702PubMed
635923716FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.RSC Med Chem2022https://conductscience.org/library/papers/35923716PubMed
719549778Structural and functional alterations of FLT3 in acute myeloid leukemia.Clin Cancer Res2009https://conductscience.org/library/papers/19549778PubMed
828516360Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.Invest New Drugs2017https://conductscience.org/library/papers/28516360PubMed
930651634Targeting FLT3 mutations in AML: review of current knowledge and evidence.Leukemia2019https://conductscience.org/library/papers/30651634PubMed
1028276286Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways.Leuk Lymphoma2017https://conductscience.org/library/papers/28276286PubMed
1130344940Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia.Oncotarget2018https://conductscience.org/library/papers/30344940PubMed
1234959180Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC).Bioorg Chem2022https://conductscience.org/library/papers/34959180PubMed
1330651561Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.Nat Commun2019https://conductscience.org/library/papers/30651561PubMed
1430737839FLT3, a prognostic biomarker for acute myeloid leukemia (AML): Quantitative monitoring with a simple anti-FLT3 interaction and flow cytometric method.J Clin Lab Anal2019https://conductscience.org/library/papers/30737839PubMed
1512529668FLT3 mutations in acute myeloid leukemia cell lines.Leukemia2003https://conductscience.org/library/papers/12529668PubMed
1634694800Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells.J Med Chem2021https://conductscience.org/library/papers/34694800PubMed
1723840454Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells.PLoS One2013https://conductscience.org/library/papers/23840454PubMed
1824227820Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.Blood2014https://conductscience.org/library/papers/24227820PubMed
1927913501Mutations in AML: prognostic and therapeutic implications.Hematology Am Soc Hematol Educ Program2016https://conductscience.org/library/papers/27913501PubMed
2024319184FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?Hematology Am Soc Hematol Educ Program2013https://conductscience.org/library/papers/24319184PubMed

See all 30 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn Papers
40790935Small-Molecule-Induced Protein Polymerization: Mechanisms and Therapeutic Implications.Biomol Ther (Seoul)2025https://conductscience.org/library/papers/40790935

Source PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39091016

GET https://conductscience.org/api/papers/v1/39091016/references?page=2